Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov-Dec;24(6):326-335.
doi: 10.4103/sjg.SJG_49_18.

Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B

Young Min Kim  1 , Hyun Phil Shin  2 , Joung Il Lee  2 , Kwang Ro Joo  2 , Jae Myung Cha  2 , Jung Won Jeon  2 , Jin Young Yoon  2 , Min Seob Kwak  2
Affiliations

Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B

Young Min Kim et al. Saudi J Gastroenterol. 2018 Nov-Dec.

Abstract

Background/aim: The goal of antiviral therapy for chronic hepatitis B (CHB) is to improve survival of the patients by achieving a complete virological response (CVR). This study aimed to evaluate long-term efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) in nucleos(t)ide analog (NA)-naïve and NA-experienced Korean patients with CHB and to determine the incidence of cirrhosis-related complications in these patients.

Patients and methods: We retrospectively reviewed medical records of all patients treated with ETV or TDF from July 2007 to January 2017. We examined CVR and analyzed the predictive factors influencing the rate of CVR and evaluated the incidences of cirrhosis-related complications.

Results: The proportion of patients who achieved CVR was 94.2% in the ETV group and 91.1% in the TDF group (P = 0.358). Among patients who achieved CVR, the mean time to CVR was 13.5 ± 14.3 months in the ETV group and 11.5 ± 10.6 months in the TDF group (P = 0.169). Positive predictive factors for CVR included the current treatment with TDF, a low hepatitis B virus DNA level, negative hepatitis B e-antigen status, and high alanine aminotransferase level in baseline laboratory test. The annual incidence rate of HCC was 127 per 10,000 patient-years (1.27% per year) in ETV group, and 85 per 10,000 patient-years (0.85% per year) in TDF group (P = 0.526).

Conclusion: Both ETV and TDF therapy resulted in a high CVR, and the annual incidence rates of HCC and other cirrhosis-related complications were not significantly different between the two treatment groups.

Keywords: Complete virological response; efficacy; entecavir; hepatitis B; tenofovir.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest

Figures

Figure 1
Figure 1
Flow chart of the enrolled participants. CHB: Chronic hepatitis B; ETV: Entecavir; TDF: Tenofovir disoproxil fumarate; LAM-R: Lamivudine-resistant; ADV-R: Adefovir-resistant; ETV-R: Entecavir-resistant
Figure 2
Figure 2
Cumulative probability of the complete virological response in patients treated with ETV
Figure 3
Figure 3
Cumulative probability of complete virological response in patients treated with TDF
Figure 4
Figure 4
The incidence rate of HCC upon TDF and ETV treatments
See this image and copyright information in PMC

References

    1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–9. - PubMed
    1. Hong WS. Seroepidemiology of type A and type B hepatitis in Seoul area. Korean J Intern Med. 1982;25:19–26.
    1. Jang KM, Woo SH, Yun DH, Lee KR, Kwon YO, Kang JY, et al. Seroepidemiologic survey on type B viral hepatitis in Inchon area. Korean J Intern Med. 1983;23:1331–6.
    1. Jang MK, Lee JY, Lee JH, Kim YB, Kim HY, Lee MS, et al. Seroepidemiology of HBV infection in South Korea, 1995 through 1999. Korean J Intern Med. 2001;16:153–9. - PMC - PubMed
    1. Joo KR, Bang SJ, Song BC, Youn KH, Joo YH, Yang S, et al. Hepatitis B viral markers of Korean adults in the late 1990s: Survey data of 70,347 health screenees. Korean J Gastroenterol. 1999;33:642–52.

MeSH terms